...
首页> 外文期刊>British Journal of Cancer >Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours
【24h】

Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours

机译:周围神经母细胞瘤凋亡机制的形态学和分子评估

获取原文

摘要

Multiple defects in apoptotic pathways have been described in peripheral neuroblastic tumours (NTs). Mitosis–karyorrhexis index (MKI) is a reliable morphological marker identifying favourable and unfavourable NTs. The extent to which apoptotic processes contribute to determine the clinical significance of MKI is still undefined. Apoptosis was investigated in a series of 110 peripheral NTs by comparing MKI to immunohistochemical and molecular apoptotic features. High MKI was found in 55 out of 110 NTs (50%) and was associated with advanced stage (P=0.007), neuroblastoma (NB) histological category (P=0.024), MYCN amplification (PP=0.011). Overall survival probability was 45% in patients with high MKI compared to 73% in patients with low MKI. In the same 110 NTs, the expression of Bcl-2, Bcl-XL, Bax and Mcl-1 was studied by immunohistochemistry, but no significant associations were found with clinicohistological features. Microarray analysis of apoptotic genes was performed in 40 out of 110 representative tumours. No significant association was found between the expression of apoptotic genes and MKI or clinicohistological features. Proliferative activity was assessed in 60 out of 110 representative tumours using Ki67 immunostaining, but no significant correlations with MKI or clinicobiological features were found. In NTs, the combination of apoptosis and proliferation as expressed by MKI is a significant prognostic parameter, although neither of them is per se indicative of the clinicobiological behaviour and outcome.
机译:在周围神经母细胞瘤(NTs)中已经描述了凋亡途径的多种缺陷。有丝分裂-核溢流指数(MKI)是一种可靠的形态学标记,可识别有利和不利的NT。凋亡过程决定MKI临床意义的程度仍不确定。通过比较MKI与免疫组织化学和分子凋亡特征,在一系列110个周围NT中研究了细胞凋亡。在110个NT中有55个发现高MKI(50%),并且与晚期(P = 0.007),成神经细胞瘤(NB)组织学类别(P = 0.024),MYCN扩增(PP = 0.011)相关。高MKI患者的总生存概率为45%,而低MKI患者为73%。在相同的110个NT中,通过免疫组织化学研究了Bcl-2,Bcl-XL,Bax和Mcl-1的表达,但未发现与临床组织学特征显着相关。在110个代表性肿瘤中的40个中进行了凋亡基因的微阵列分析。在凋亡基因的表达与MKI或临床组织学特征之间未发现显着关联。使用Ki67免疫染色评估了110个代表性肿瘤中60个的增殖活性,但未发现与MKI或临床生物学特征显着相关。在NTs中,由MKI表达的凋亡和增殖的组合是重要的预后参数,尽管它们本身均不能指示临床生物学行为和结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号